Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

3 Blue-Chip Marvels Trading At Unmissable Prices: GlaxoSmithKline plc, easyJet plc And National Grid plc

Royston Wild explains why GlaxoSmithKline plc (LON: GSK), easyJet plc (LON: EZJ) and National Grid plc (LON: NG) should be on the shopping list of all savvy value seekers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three stocks that provide stunning bang for one’s buck.

GlaxoSmithKline

The problem of serious patent losses continues to stunt investor appetite for pharma plays such as GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Shares in the firm have steadily declined in recent weeks and have shed more than 10% since mid-April, but I believe that this recent weakness represents a fresh buying opportunity.

You see, while revenues losses from the likes of its Advair asthma treatment are likely to remain a bugbear, GlaxoSmithKline is throwing everything including the kitchen sink at producing the next line of profits drivers. The company currently has around 40 products in Phase II or III development, and while the business of drugs development is often fraught with delays and heavy capital drain, I reckon GlaxoSmithKline’s exceptional track record in these matters should underpin excellent earnings growth — indeed, its Tivicay anti-HIV drug is touted as a future superstar.

Of course the pills play’s bubbly pipeline is not set to offset the impact of key exclusivity losses just yet, and GlaxoSmithKline is anticipated to punch a further 11% earnings decline in 2015. Still, the fruits of these labours are expected to translate into tangible gains from next year, and a 7% uptick is currently pencilled in by the City. Accordingly a P/E multiple of 16.8 times for this year falls to just 15.5 times for 2015, around the watermark of 15 times that indicates attractive value.

On top of this, GlaxoSmithKline is also on course to maintain market-beating dividend yields in the coming years, the company having pledged payouts of 80p per share through to 2017. These figures create a large yield of 5.5% during this period, and I believe a backcloth of strong earnings growth should drive rewards still higher looking further down the road.

easyJet

I reckon that budget carrier easyJet (LSE: EZJ) is a sound choice for those seeking delicious value for money. Demand for cheap travel from holidaymakers and business travellers alike is showing no signs of slowing, a trend which prompted Europe’s airlines to boost the number of seats in the short-haul market to 20.2 million seats in October-March, up 5.2% on an annualised basis.

With easyJet expanding the number of planes, routes and airports from which it operates — and boosted by the likelihood of lower fuel prices looking ahead — I believe earnings should continue soaring higher. This view is shared by the number crunchers, and the airline is expected to punch growth of 14% and 11% for the years concluding September 2015 and 2016 correspondingly. As a result the carrier boasts ultra-low P/E ratings of 13.2 times and 11.9 times for these years.

In line with this bubbly earnings outlook, easyJet is predicted to hike the dividend from 45.4p per share last year to 53.1p in the current period, producing a decent yield of 3.1%. And expectations of a further raise in 2016, to 59.5p, drives the yield to a juicy 3.5%.

National Grid

I believe that National Grid’s (LSE: NG) (NYSE: NGG.US) vertically-integrated operations make it a more attractive selection that any of the UK’s other utilities giants, its model allowing it to dodge regulatory scrutiny over its profitability and therefore any potentially-draconian action. Rather, the London firm is benefitting from OFGEM’s RIIO price controls — measures designed to curtail capital seepage — a terrific omen for earnings and dividend hunters.

With National Grid also aggressively building its asset base in the UK as well as North America, I believe shareholder returns should head for the skies in the coming years. In the meantime, the effect of heavy investment is expected to push earnings fractionally lower in the year concluding March 2016, although a 3% bounce in the following 12 months is a sign of things to come. And this predicted uptick also pushes a decent earnings multiple of 15.6 times for this year to an even-better 15.1 times next year.

Subsequently the City also expects dividends to continue steadily rising, and a payment of 42.87p per share last year is anticipated to advance to 44.4p in the current period, resulting in a monster 5% yield. And this rises to 5.1% for 2017 amid expectations of a 45.6p reward.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Forget high yields? Here’s the smart way to build passive income with dividend shares

Stephen Wright outlines how investors looking for passive income can put themselves in the fast lane with dividend shares.

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

15,446 Diageo shares gets me a £1,000 monthly second income. Should I?

Diageo has been a second-rate income stock for investors over the last few years. But the new CEO sees potential…

Read more »

Investing Articles

2 FTSE 100 stocks to target epic share price gains in 2026!

Looking for blue-chip shares to buy? Discover which two FTSE 100 stocks our writer Royston Wild thinks could explode in…

Read more »

A row of satellite radars at night
Investing Articles

If the stock market crashes in 2026, I’ll buy these 2 shares like there’s no tomorrow

These two shares have already fallen 25%+ in recent weeks. So why is this writer wating for a stock market…

Read more »

British Pennies on a Pound Note
Investing Articles

How much money does someone really need to start buying shares?

Could it really be possible to start buying shares with hundreds of pounds -- or even less? Christopher Ruane weighs…

Read more »

Two gay men are walking through a Victorian shopping arcade
Investing Articles

With Versace selling for £1bn, what does this tell us about the valuations of the FTSE 100’s ‘fashionable’ stocks?

Reflecting on the sale of Versace, James Beard reckons the valuations of the FTSE 100’s fashion stocks don’t reflect the…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

Want to stuff your retirement portfolio with high-yield shares? 5 to consider that yield 5.6%+

Not everyone wants to have a lot of high-yield shares in their portfolio. For those who might, here's a handful…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How much do you need in a SIPP to target a £3,658 monthly passive income?

Royston Wild discusses a 9.6%-yielding fund that holds global stocks -- one he thinks could help unlock an enormous income…

Read more »